Synagis, also known as palivizumab, is a medication used to prevent serious respiratory syncytial virus (RSV) infections in high-risk infants and young children. RSV is a common virus that can cause severe respiratory illness in infants, especially those born prematurely or with certain medical conditions.

This medication works by providing passive immunity against RSV, helping to protect vulnerable children from developing severe complications such as pneumonia or bronchiolitis. It is typically administered as a monthly injection during the RSV season, which usually runs from November to April.

Synagis has been shown to be effective in reducing the risk of RSV-related hospitalizations in high-risk infants, making it an important tool in preventing serious respiratory infections in this vulnerable population. However, it is important to note that Synagis is not a treatment for RSV infection once it has occurred, but rather a preventive measure to reduce the likelihood of severe illness.

As with any medication, Synagis may cause side effects in some children, such as injection site reactions or mild fever. It is important to discuss any concerns or questions about this medication with your healthcare provider to determine if it is the right choice for your child.

Overall, Synagis is a valuable tool in protecting high-risk infants and young children from serious RSV infections. By working with your healthcare provider to determine the best course of action for your child, you can help ensure their health and well-being during the RSV season.